SCHEDULE: BlackRock Discloses 7.1% Stake in Olema Pharmaceuticals

BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting beneficial ownership of 7.1% of Olema Pharmaceuticals, Inc. common stock as of June 30, 2026.

Summary

• BlackRock, Inc. has amended its Schedule 13G filing to report its beneficial ownership of Olema Pharmaceuticals, Inc. common stock.
• As of June 30, 2026, BlackRock beneficially owns 6,244,212 shares, representing 7.1% of the class of securities.
• This ownership includes 6,138,842 shares for which BlackRock has sole voting power and 6,244,212 shares for which it has sole dispositive power.
• The filing indicates that no single person's interest in Olema Pharmaceuticals, Inc. common stock exceeds five percent of the total outstanding shares.
• BlackRock, Inc. is identified as a holding company (HC) for reporting purposes.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It is a routine disclosure of institutional ownership and does not provide new operational or financial information about Olema Pharmaceuticals itself.

Positives

• BlackRock, a significant institutional investor, has disclosed a substantial ownership stake, which can be viewed as a positive signal of confidence in Olema Pharmaceuticals.
• The clear reporting of sole voting and dispositive power indicates direct control over the shares held.

Negatives

• The filing does not contain any negative financial results or operational challenges for Olema Pharmaceuticals; it solely reports BlackRock's ownership.

Risks

• Potential for significant share sales by BlackRock could impact Olema Pharmaceuticals' stock price.
• Changes in BlackRock's investment strategy could lead to divestment from Olema Pharmaceuticals.

Future Outlook

This filing is a disclosure of ownership and does not contain forward-looking statements or guidance regarding Olema Pharmaceuticals' future performance.

Management Comments

• BlackRock, Inc. certifies that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that significant stake disclosures by major asset managers like BlackRock often signal institutional conviction in a company's long-term prospects, particularly in the biotechnology sector where clinical trial progress and regulatory approvals are key value drivers.

Stakeholder Impact

• Shareholders: The disclosure may influence investor perception of Olema Pharmaceuticals due to BlackRock's significant stake, potentially impacting trading activity.
• Management of Olema Pharmaceuticals: The increased visibility from a major institutional holder could lead to greater scrutiny or engagement on corporate strategy.
• Potential Investors: The filing provides information on institutional ownership, which is a factor considered in investment analysis.

Next Steps

• BlackRock will continue to monitor its beneficial ownership percentage and file amendments as required by SEC regulations.
• Olema Pharmaceuticals will continue its operations and clinical development programs.

Key Dates

Keywords

Olema Pharmaceuticals, BlackRock, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Management